Dianthus Therapeutics (NASDAQ:DNTH) Given Buy Rating at HC Wainwright

Key Points

• Analysts at HC Wainwright have reiterated a "buy" rating for Dianthus Therapeutics (NASDAQ:DNTH), with a target price of $40.00, indicating a potential upside of 50.94%.
• Despite an overall positive outlook, the company reported a quarterly loss of ($0.88) earnings per share, which was below analysts' expectations.
• Institutional investors hold 47.53% of Dianthus Therapeutics' stock, with several large transactions in recent quarters significantly increasing their stakes.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report)'s stock had its "buy" rating reiterated by analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $40.00 target price on the stock. HC Wainwright's price target points to a potential upside of 50.94% from the stock's current price.

A number of other analysts have also weighed in on the stock. Robert W. Baird lowered their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Wedbush lifted their target price on Dianthus Therapeutics from $34.00 to $42.00 and gave the company an "outperform" rating in a research note on Thursday, August 21st. Finally, William Blair started coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They issued an "outperform" rating on the stock. Seven investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $54.00.

Dianthus Therapeutics Stock Up 7.5%

Dianthus Therapeutics stock opened at $26.50 on Monday. The stock has a 50-day simple moving average of $21.27 and a 200 day simple moving average of $20.03. The stock has a market capitalization of $853.04 million, a price-to-earnings ratio of -8.15 and a beta of 1.46. Dianthus Therapeutics has a 12-month low of $13.36 and a 12-month high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million. As a group, sell-side analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

Large investors have recently bought and sold shares of the business. Raymond James Financial Inc. bought a new position in Dianthus Therapeutics in the second quarter valued at approximately $27,000. US Bancorp DE lifted its position in Dianthus Therapeutics by 2,013.3% in the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock valued at $29,000 after acquiring an additional 1,510 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Dianthus Therapeutics in the 4th quarter valued at $59,000. GAMMA Investing LLC boosted its stake in Dianthus Therapeutics by 3,030.6% in the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock worth $70,000 after purchasing an additional 3,758 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock worth $80,000 after purchasing an additional 3,317 shares in the last quarter. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.